Startseite Medizin Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis
Artikel Open Access

Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis

  • Junhong Guo , Jiangtao Yu , Xiaojie Song und Haixia Mi EMAIL logo
Veröffentlicht/Copyright: 7. Mai 2017

Abstract

Objective

To evaluate the diagnostic value of combination detection of serum cancer antigen 125 (CA125), carbohydrate antigen 19-9 (CA199) and carci noembryonic antigen(CEA) in patients with epithelial ovarian cancer by pooling the open published studies according to meta-analysis method.

Methods

Diagnostic studies related to combination detection of serum CA125, CA199 and CEA in patients with epithelial ovarian cancer were electronic searched in the databases of PubMed, Cochrane, Google scholar, EMBASE, ISI Web of Knowledge and CNKI by two independent reviewers. The combined diagnostic sensitivity, specificity, positive likely hood ratio (+LR), negative likely hood ratio (-LR), diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) were pooled by Med DiSc1.4 software.

Results

Twelve prospective diagnostic publications were finally fulfilled the inclusion criteria and were included in this meta-analysis. The pooled diagnostic sensitivity specificity, positive likely hood ratio, negative likely hood ratio, diagnostic odds ratio, and AUC were 0.90 (95%CI: 0.80 to 0.92), 0.83 (95%CI: 0.80 to 0.86), 5.35(95%CI:3.90 to 7.33), 0.13 (95%CI: 0.10 to 0.16), 48.53 (95%CI: 29.91 to 78.72) and 0.92 (95%C: 0.89 to 0.94) respectively by fixed or random effect model. No publication bias was found according to the funnel plot and line regression test (t=-1.34, P=0.21).

Conclusion

Combination detection serum CA125, CA199 and CEA was a promising biomarker forepithelial ovarian cancer diagnosis with relative high sensitivity and specificity.

1 Introduction

In the past two decades, several serum biomarkers for epithelial ovarian cancer diagnosis have been studied, such as Ca125, Ca199, CEA, HE4 and et al [1]. Ca125 is also known as mucin 16 or MUC16, a protein that in humans is encoded by the MUC16 gene. It was found serum Ca125 had been elevated in patients with specific types of cancers, which could be a potential biomarker [2]. Several studies have discussed the serum Ca125 level in ovarian cancer patients and found about 80% of advanced patients had elevated levels of Ca125 in their blood [3,4]. However, studies also found that serum Ca125 can also elevated in individuals without ovarian cancer which made the diagnostic specificity relative low. Previously studies [5,6] indicated Ca199 can be elevated in gastrointestinal cancer, such as colorectal cancer, esophageal cancer and pancreatic cancer. Published study [7] showed elevated Ca199 also can be detected in ovarian cancer patients in their bloods. CEA was one of the most used serum biomarker for solid malignant carcinoma diagnosis such as lung cancer, esophageal cancer colorectal cancer and epithelial ovarian cancer. However, the diagnostic sensitivity or specificity was not high enough of a single serum biomarker of Ca125, Ca199 or CEA for diagnosis of epithelial ovarian cancer. Then, combination detection several serum biomarkers may increase the diagnostic value [8-10]. Several diagnostic studies had discussed the combination detection serum CA125, CA199 and CEA in epithelial ovarian cancer patients with relative high sensitivity and specificity [11-13]. However, because of the small sample size of each individual study, the conclusion was not consistent. In this meta-analysis, we searched the related databases and included open published studies related to combination detection serum CA125, CA199 and CEA in diagnostic epithelial ovarian cancer in order to provide more evidence for its clinical use.

2 Material and methods

2.1 Publication searching

Diagnostic studies related to combination detection serum CA125, CA199 and CEA in patients with epithelial ovarian cancer were electronic searched in the databases of PubMed, Cochrane, Google scholar, EMBASE, ISI Web of Knowledge and CNKI by two independent reviewers (Guo Junhong&Yu Jiangtao). The searching words were “ epithelial ovarian cancer”, “malignant ovary tumor”, “ca 125 antigen”, “ca 125”, “cancer antigen 125”, “CA199”, “carbohydrate antigen 19-9”, “CEA”, “carcino-embryonic antigen”. All potential relevant studies were assessed in detail and additional and all citations of the included articles were further evaluated in order to identify additional suitable studies.

2.2 Data extraction

The data of each included study was extracted by two reviewers Guo JH & Mi HX independently. The general character such as year of publication, first and corresponding author and control type were extracted from each of the included studies. The case number of the true positive (tp), false positive (fp), false negative (fn) and true negative(tn) of the each study were also recorded and cross checked by two reviewers.

2.3 Statistical analysis

Med DiSc1.4 (http://www.biomedsearch.com/nih/Meta-DiSc-software-meta-analysis.) and Stata11.0 (http://www.stata.com; Stata Corporation, College Station, TX) statistical software were used to do all the statistical analysis. Statistical heterogeneity across the included studies was assessed by chi-square/Cochran-Q test and demonstrated by I2 for the effect size of sensitivity, specificity, positive likely hood ratio, negative likely hood ratio and diagnostic odds ratio. Without statistical heterogeneity, the effect size was pooled by fixed effect model, otherwise it was pooled by random effect model. P<0.05 was considered as statistical significant.

3 Results

3.1 Publication searching results

After searching the related databases, 712 papers were initially identified. And 661 articles were excluded after reading the title and abstract. 39 publications were excluded after reading the whole text paper. Finally 12 prospective diagnostic publications were fulfilled the inclusion criteria and were included in this meta-analysis [11-22]. Six studies used benign ovarian tumor as the control group, 3 publications used healthy subjects as the control group and left 3 articles used mixed subjects as the controls. The general characteristics of included 12 papers were demonstrated in Table 1.

Table 1

General characteristics of included studies

First authorYearTPFPFNTNSenSepControl type
Luo XH200626163360.900.69Benign ovarian tumor
Shao JL200736147240.840.63Benign ovarian tumor
Song XL200740102800.950.89Mixed
Pu ZY20105048460.860.92Healthy subjects
Li L20106936470.920.94Healthy subjects
Huang F201037133820.930.86Mixed
Qian M20104246360.880.90Benign ovarian tumor
Liu L20117778540.910.89Benign ovarian tumor
Zhang FL201128212520.930.71Mixed
Yu B20113784330.900.80Healthy subjects
Jiang J201471169640.890.80Benign ovarian tumor
Zhang T2016592451350.920.85Benign ovarian tumor

3.2 Statistical heterogeneity

Statistical heterogeneity across the included studies was assessed by chi-square/Cochran-Q test and demonstrated by I2 for the effect size of sensitivity, specificity, positive likely hood ratio, negative likely hood ratio and diagnostic odds ratio. Significant heterogeneity was found in the effect size of specificity, positive likely hood ratio and diagnostic odds ratio(P 003<0.05). These effect size were pooled by random effect model, Table 2.

Table 2

Statisticalheterogeneityevaluationby chi-square/ Cochran-Q test

Effect sizeChi-square/Cochran-QI2 (%)P
Sensitivity5.930.00.88
Specificity36.9270.20.0001
Positive likely hood ratio43.5274.70.0000
Negative likely hood ratio8.840.00.63
Diagnostic odds ratio20.6246.60.03

3.3 Pooled sensitivity

Without significant statistical heterogeneity, diagnostic sensitivity was pooled by fixed effect model. The pooled diagnostic sensitivity of combination detection serum CA125, CA199 and CEA for epithelial ovarian cancer was 0.90 (95%CI: 0.80 to 0.92), Figure 1.

Figure 1 Forest plot for diagnostic sensitivity of ovarian cancer by combination detection serum CA125 CA199 and CEA.
Figure 1

Forest plot for diagnostic sensitivity of ovarian cancer by combination detection serum CA125 CA199 and CEA.

3.4 Pooled specificity

With significant statistical heterogeneity, diagnostic specificity was pooled by random effect model. The pooled diagnostic specificity of combination detection serum CA125, CA199 and CEA for epithelial ovarian cancer was 0.83 (95%CI: 0.80 to 0.86), Figure 2.

Figure 2 Forest plot for diagnostic specificity of ovarian cancer by combination detection serum CA125 CA199 and CEA.
Figure 2

Forest plot for diagnostic specificity of ovarian cancer by combination detection serum CA125 CA199 and CEA.

3.5 Pooled positive likely hood ratio

Significant heterogeneity was found in the effect size of positive likely hood ratio. The pooled positive likely hood ratio was 5.35(95%CI:3.90 to 7.33) by random effect model, Figure 3.

Figure 3 Forest plot for positive likely hood ratio by combination detection serum CA125 CA199 and CEA.
Figure 3

Forest plot for positive likely hood ratio by combination detection serum CA125 CA199 and CEA.

3.6 Pooled negative likely hood ratio

The negative likely hood ratio was pooled by fixed effect model without statistical heterogeneity. It was 0.13 with its 95%CI of 0.10 to 0.16, Figure 4.

Figure 4 Forest plot for negative likely hood ratio by combination detection serum CA125 CA199 and CEA.
Figure 4

Forest plot for negative likely hood ratio by combination detection serum CA125 CA199 and CEA.

3.7 Pooleddiagnostic odds ratio

The diagnostic odds ratio was pooled by random effect model for significant statistical heterogeneity. The pooled diagnostic odds ratio was 48.53 (95%CI: 29.91 to 78.72), Figure 5.

Figure 5 Forest plot for diagnostic odds ratio by combination detection serum CA125 CA199 and CEA.
Figure 5

Forest plot for diagnostic odds ratio by combination detection serum CA125 CA199 and CEA.

3.8 Pooled SCOR

The pooled area under the receiver operating characteristic curve (ROC) was 0.92 (95%C: 0.89 to 0.94), Figure 6.

Figure 6 The pooled receiver operating characteristic curve of combination detection serum CA125 CA199 and CEA.
Figure 6

The pooled receiver operating characteristic curve of combination detection serum CA125 CA199 and CEA.

3.9 Subgroup analysis

We further performed subgroup analysis for diagnostic sensitivity, specificity, positive likely hood ratio, negative likely hood ratio, diagnostic odds ratio, and AUC according the control type. The subgroup analysis results were showed in Table 3.

Table 3

Subgroup analysis according to control type

Effect sizeBenign ovarian tumorHealthy subjects
Sen0.89 (0.85 to 0.92)0.90 (0.84 to 0.94)
Sep0.81 (0.77 to 0.85)0.89 (0.83 to 0.94)
+LR4.51 (2.94 to 6.90)8.37 (3.73 to 18.77)
-LR0.14 (0.10 to 0.19)0.12 (0.08 to 0.18)
DOR34.37 (17.37 to 67.98)75.45 (32.10 to 177.34)
AUC0.93 (0.89to 0.95)0.91 (0.87 to 0.96)

3.10 Publication bias

No publication bias was found according to the funnel plot (Figure 7) and line regression test (t=-1.34, P=0.21), Figure 7.

Figure 7 Funnel plot for evaluation publication bias.
Figure 7

Funnel plot for evaluation publication bias.

4 Discussion

Epithelial ovarian cancer is one of the most diagnosed malignant carcinoma in females [23]. It has been reported that epithelial ovarian cancer was the 2nd most common malignant gynecological carcinoma with an increasing incidence and prevalence [24,25]. Progress has been made for epithelial ovarian cancer early diagnosis; however, most patients were diagnosed in advanced stage with relative poor prognosis (mean 5-year survival rate of 37.6%) [26,27]. The poor 5-year survival rate for epithelial ovarian cancer patients is the result of aggressive biological behavior and a lack of early detection method. It was reported about 70% of epithelial ovarian cancer patients were diagnosed at advanced stage [25]. So, high sensitivity, specificity and accurate methods are need for detection of epithelial ovarian cancer especially for early stage or high-risk subjects. Serum cancer antigen 125 (CA125) are mostly used tumor serum biomarker for several cancers screening including epithelial ovarian cancer, endometrial cancer, cervical cancer, pancreatic cancer, colon cancer, breast cancer and et al. However, the diagnostic sensitivity were not satisfactory. USPSTF stated that detection serum CA125 had almost no effect on reducing ovarian mortality, while instead increasing the risk of harm including diagnostic procedure and decline in quality of life [26]. CA199 is a glucolipid on the cell membrane and a kind of mucin tumor markers, its molecular weight is more than 1 000 Kd. CA199 was another biomarker used for detection of epithelial ovarian cancer. However, it had limited clinical use for epithelial ovarian cancer screening with not satisfactory diagnostic accuracy. CEA is one of the most used tumor markers in clinical application. It has important diagnostic value for gynecology malignant tumor, breast cancer [28], lung cancer [29] and other digestive system malignant tumors. However, single detection serum CA125, CA199 and CEA had little value for epithelial ovarian cancer detection with low sensitivity or specificity. Several published studies has demonstrated that combination detection serum CA125, CA199 and CEA can provide satisfactory diagnostic value for epithelial ovarian cancer [15,16]. However, because of the small sample size of each individual study, the conclusion was not consistent. So, in our present meta-analysis we included 12 prospective diagnostic trials evaluating the diagnostic value of combination detection CA125, CA199 and CEA for epithelial ovarian cancer diagnosis. The results showed pooled diagnostic sensitivity specificity, positive likely hood ratio, negative likely hood ratio, diagnostic odds ratio, and AUC were 0.90 (95%CI: 0.80 to 0.92), 0.83 (95%CI: 0.80 to 0.86), 5.35(95%CI:3.90 to 7.33), 0.13 (95%CI: 0.10 to 0.16), 48.53 (95%CI: 29.91 to 78.72) and 0.92 (95%C: 0.89 to 0.94) respectively. These results indicated that combination detection serum CA125, CA199 and CEA was promising biomarker for epithelial ovarian cancer with relative high sensitivity and specificity.

However, there were several limitations for this meta-analysis. Firstly, only studies published in Chinese or English were searched in the databases and included in this study. This may result in publication searching bias. Secondly, significant statistical heterogeneity was existed in this meta-analysis, which may decrease the statistical power and weaken the conclusion. Thirdly, the original studies included in this manuscript did not use the same cut-off value to determine the serum protein of CA125,CA199 and CEA negative or positive. This is an important clinical heterogeneity across the original studies. Fourthly, for the included12 references, the patients were of the same source population, which may limited, its clinical use.

  1. Conflict of interest: No authors report any conflict of interest.

References

[1] Komai K, Nishida T. Tumor marker in ovarian cancer. Gan To Kagaku Ryoho 2002;29:481-486Suche in Google Scholar

[2] Bast RC, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the uture. Int J Biol Markers 1998; 13(4): 179-18710.1177/172460089801300402Suche in Google Scholar

[3] Bocheva Y, Bochev P, Ivanov S. Ca-125 in diagnosis and monitoring of patients with ovarian cancer. Akush Ginekol (Sofiia) 2015; 54(1): 11-17Suche in Google Scholar

[4] Alexandre J, Brown C, Coeffic D. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. Br J Cancer 2012; 106(4): 633-637 10.1038/bjc.2011.593Suche in Google Scholar PubMed PubMed Central

[5] Shiozawa S, Tsuchiya A, Kim DH, Ogawa K. Prognostic significance of CA19-9 levels in patients with pancreatic cancer.Nihon Rinsho 2006; 64 Suppl 1: 297-300Suche in Google Scholar

[6] Liang Y, Wang W, Fang C. Clinical significance and diagnostic value of serum CEA, CA19-9 and CA72-4 in patients with gastric cancer. Oncotarget 2016; 7(31): 49565-4957310.18632/oncotarget.10391Suche in Google Scholar PubMed PubMed Central

[7] Canney PA, Wilkinson PM, James RD, Moore M. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125. Br J Cancer 1985; 52(1): 131-13310.1038/bjc.1985.161Suche in Google Scholar PubMed PubMed Central

[8] Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol 2014;35:6127-613810.1007/s13277-014-1811-6Suche in Google Scholar PubMed

[9] Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, Schlumbrecht M. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta-analysis. Int J Gynecol Cancer 2016;26:1586-159310.1097/IGC.0000000000000804Suche in Google Scholar PubMed

[10] Lan Z, Fu D, Yu X, Xi M. Diagnostic values of osteopontin combined with CA125 for ovarian cancer: a meta-analysis. Fam Cancer 2016;15:221-23010.1007/s10689-015-9847-3Suche in Google Scholar PubMed

[11] Yu B. The dinieal value of the combined detection of CEA, CAl25 and CAl9-9 in ovarian atlrdliOm diagnasis. Jurnal of Binzhou Medical University 2011;34:294-295Suche in Google Scholar

[12] Jiang J, Deng XY, Hu XH. Clinical significance of the combined detection of CA125, CA199 and CE in diagnosis of ovarian cancer. Chinese Journal of Laboratory Diagnosis 2014;18:1145-1148Suche in Google Scholar

[13] Zhang T, Cheng XJ, Zhang B. CA199, Clinical value of combined detection serum CA125 and CEA for ovarian cancer diagnosis. Guizhou Medical Journal 2016;40:973-975Suche in Google Scholar

[14] Luo XH, Ch D, Pan KY, Wang Y, Zeng HY. The value of combined serum CA125, CA199 and CEA test for ovarian cancer diagnosis. Journal of Clinical and Experimental Medicine 2006;5:878-879Suche in Google Scholar

[15] Shao LJ, Xu RL, Hu T. Combination detection serum CA125,CA199 and CEA for ovarian cancer diagnosis. Journal of Radioimmunology 2007;20:92-93Suche in Google Scholar

[16] Song XL, Wang GS, Luo JM, Zhao ZL. Diagnostic value for combined detection serum CA125, CA199 and CEA in patients with ovarian cancer. Journal of Henan University(Medical Science) 2007;26:70-71Suche in Google Scholar

[17] Huang F. Serum CA125,CA199 and CEA combined detection for ovarian cancer diagnosis. Guangxi Medical Journal 2010;32:424-425Suche in Google Scholar

[18] Li L, Liao JX. The Clinical Diagnostic Value of joint inspection of Serum CEA、CA19-9、CA125 in the Patients with Ovarian Cancer. Journal of Modern Clinical Medicine 2010;36:122-124Suche in Google Scholar

[19] Pu ZY, Liu FJ, Liu YY. Clinical evaluation serum CA125, CEA and CA19-9 combined detection for ovarian cancer diagnosis. West China Medical Journal 2010:1879-1880Suche in Google Scholar

[20] Qian M, Yuan JJ, Wang XH, Shu XC.Diagnosis and Prognosis Value of the Serum CA125、CA199、CEA Detection in Patients with Epithelinl Ovarian Cancer. China Practical Medical 2010;05:53-54Suche in Google Scholar

[21] Liu L, Zhang MK, Chen JL, Huang RQ.The significance of serum CA125,199 and CEA test in the diagnosis of ovarian cancer. Chongqing Medicine 2011;40:2423-2424,2426Suche in Google Scholar

[22] Zhang FL. Ovarian cancer diagnosis by combination detection serum CEA, CA125and CA199. Chinese Journal of Misdiagnostics 2011;11:4646-4647Suche in Google Scholar

[23] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-3010.3322/caac.21332Suche in Google Scholar PubMed

[24] Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55:3-2310.1097/GRF.0b013e31824b4611Suche in Google Scholar PubMed

[25] Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 201610.1016/j.bpobgyn.2016.08.006Suche in Google Scholar PubMed

[26] Pavlik EJ. Ovarian cancer screening effectiveness: A realization from the UK Collaborative Trial of Ovarian Cancer Screening. Womens Health (Lond) 2016;12:475-47910.1177/1745505716666096Suche in Google Scholar PubMed PubMed Central

[27] Voelker R. Ovarian Cancer Screening Tests Don’t Pass Muster. JAMA 2016;316:153810.1001/jama.2016.14614Suche in Google Scholar PubMed

[28] Tang S, Zhou F, Sun Y, Wei L, Zhu S, Yang R, Huang Y, Yang J. CEA in breast ductal secretions as a promising biomarker for the diagnosis of breast cancer: a systematic review and meta-analysis. Breast Cancer 2016;23:813-81910.1007/s12282-016-0680-9Suche in Google Scholar PubMed

[29] Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y. Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer 2013;80:45-4910.1016/j.lungcan.2013.01.002Suche in Google Scholar PubMed

Received: 2017-1-26
Accepted: 2017-2-2
Published Online: 2017-5-7

© 2017 Junhong Guo et al.

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Regular Articles
  2. Intravascular treatment of left subclavian artery aneurysm coexisting with aortic coarctation in an adult patient
  3. Regular Articles
  4. Effect of electrical stimulation on blood flow velocity and vessel size
  5. Regular Articles
  6. Live birth pregnancy outcome after first in vitro fertilization treatment in a patient with Systemic Lupus Erythematosus and isolated high positive IgA anti-β2glycoprotein I antibodies: a case report
  7. Regular Articles
  8. Periodontal ligament stem cells regulate apoptosis of neutrophils
  9. Regular Articles
  10. Platelet-rich fibrin (PRF) in implants dentistry in combination with new bone regenerative flapless technique: evolution of the technique and final results
  11. Regular Articles
  12. The significance of strong ion gap for predicting return of spontaneous circulation in patients with cardiopulmonary arrest
  13. Regular Articles
  14. Clinicopathology of EpCAM and EGFR in human epithelial ovarian carcinoma
  15. Regular Articles
  16. Intraosseous lipoma of the mandibula: A case report and review of the literature
  17. Regular Articles
  18. Transurethral resection of the prostate, bladder explosion and hyponatremic encephalopathy: a rare case report of malpractice
  19. Regular Articles
  20. Brain strokes related to aortic aneurysma – the analysis of three cases
  21. Regular Articles
  22. Effect of Bicyclol tablets on drug induced liver injuries after kidney transplantation
  23. Regular Articles
  24. Plasma free fatty acids in hyperemesis gravidarum pregnancy
  25. Regular Articles
  26. Impact of chromosomal rearrangement upon DNA methylation patterns in leukemia
  27. Regular Articles
  28. Gefitinib versus docetaxel in treated non-small-cell lung cancer: a meta-analysis
  29. Regular Articles
  30. The clinical characteristics of patients with chronic idiopathic anal pain
  31. Regular Articles
  32. Bone tunnel impaction reduced the tibial tunnel enlargement
  33. Regular Articles
  34. Effects of S-1 combined with radiotherapy in the treatment of nasopharyngeal cancer: a meta-analysis based on randomized controlled trials
  35. Regular Articles
  36. Predictions and outcomes of atrial fibrillation in the patients with acute myocardial infarction
  37. Regular Articles
  38. An accuracy study of the Intracavitary Electrocardiogram (IC-ECG) guided peripherally inserted central catheter tip placement among neonates
  39. Regular Articles
  40. Serum CA125, CA199 and CEA combined detection for epithelial ovarian cancer diagnosis: A meta-analysis
  41. Regular Articles
  42. Surface coil intensity correction in magnetic resonance imaging in spinal metastases
  43. Regular Articles
  44. Muscle stem cell and physical activity: what point is the debate at?
  45. Regular Articles
  46. MicroRNA let-7g directly targets forkhead box C2 (FOXC2) to modulate bone metastasis in breast cancer
  47. Regular Articles
  48. Monitoring health inequalities at the municipal level: Lithuanian experience
  49. Regular Articles
  50. Role of Epstein-Barr virus in the development of nasopharyngeal carcinoma
  51. Regular Articles
  52. Thrombectomy combined with indwelling-catheter thrombolysis is more effective than pure thrombectomy for the treatment of lower extremity deep venous thrombosis
  53. Regular Articles
  54. Expression of Hepcidin and Neogenin in colorectal cancer
  55. Regular Articles
  56. Carnitine and adiponectin levels in breast cancer after radiotherapy
  57. Regular Articles
  58. Pathophysiology of meningioma growth in pregnancy
  59. Regular Articles
  60. Causal neuro-immune relationships at patients with chronic pyelonephritis and cholecystitis. Correlations between parameters EEG, HRV and white blood cell count
  61. Regular Articles
  62. Measuring efficiency of secondary healthcare providers in Slovenia
  63. Regular Articles
  64. Galectin-3 expression in colorectal cancer and its correlation with clinical pathological characteristics and prognosis
  65. Regular Articles
  66. Model for studying anti- allergic drugs for allergic conjunctivitis in animals
  67. Regular Articles
  68. Barriers perceived by nurses in the optimal treatment of postoperative pain
  69. Regular Articles
  70. Tumor microenvironment in treatment of glioma
  71. Regular Articles
  72. Delirium risk of dexmedetomidine and midazolam in patients treated with postoperative mechanical ventilation: A meta-analysis
  73. Regular Articles
  74. Hemangioma of the rib: a rare case report and literature review
  75. Regular Articles
  76. The diagnostic accuracy of conventional forceps biopsy compared to ESD
  77. Regular Articles
  78. Increased miR-25 expression in serum of gastric cancer patients is correlated with CA19-9 and acts as a potential diagnostic biomarker
  79. Regular Articles
  80. Therapeutic nanomedicine surmounts the limitations of pharmacotherapy
  81. Regular Articles
  82. Relationship between PD-L1 expression and clinical characteristics in patients with breast invasive ductal carcinoma
  83. Regular Articles
  84. Trypsinogen activation peptide induces HMGB1 release from rat pancreatic acinar cells
  85. Regular Articles
  86. The effective regulation of pro- and anti-inflammatory cytokines induced by combination of PA-MSHA and BPIFB1 in initiation of innate immune responses
  87. Regular Articles
  88. Cell based therapeutic approach in vascular surgery: application and review
  89. Regular Articles
  90. Clinical efficacy of alprostadil combined with α-lipoic acid in the treatment of elderly patients with diabetic nephropathy
  91. Regular Articles
  92. Professional burnout and concurrent health complaints in neonatal nursing
  93. Regular Articles
  94. Esophageal xanthoma: presence of M2 macrophages suggests association with late inflammatory and reparative processes
  95. Regular Articles
  96. Cone beam computed tomography analysis in 3D position of maxillary denture
  97. Regular Articles
  98. CK20 mRNA expression in serum as a biomarker for colorectal cancer diagnosis: A meta-analysis
  99. Regular Articles
  100. Serum AFU, 5’-NT and AFP as biomarkers for primary hepatocellular carcinoma diagnosis
  101. Regular Articles
  102. Absolute reliability and concurrent validity of hand held dynamometry and isokinetic dynamometry in the hip, knee and ankle joint: systematic review and meta-analysis
  103. Regular Articles
  104. The Fountain of Youth: A tale of parabiosis, stem cells, and rejuvenation
  105. Regular Articles
  106. Foam sclerotherapy during shunt surgery for portal hypertension and varices
  107. Regular Articles
  108. Insomnia and depression: Japanese hospital workers questionnaire survey
  109. Regular Articles
  110. Serum NF-κBp65, TLR4 as biomarker for diagnosis of preeclampsia
  111. Regular Articles
  112. Docetaxel/cisplatin therapy in myasthenia gravis with hypertension/diabetes
  113. Regular Articles
  114. Fluid resuscitation and markers of glycocalyx degradation in severe sepsis
  115. Regular Articles
  116. Modified Sauve-Kapandji procedure for patients with old fractures of the distal radius
  117. Regular Articles
  118. Bile leakage after liver transplantation
  119. Regular Articles
  120. VEGF overexpression predicts poor survival in hepatocellular carcinoma
  121. Regular Articles
  122. Galen vein aneurysm– challenge for treatment
  123. Regular Articles
  124. Retrieval of a broken sewing needle from the sacrum aided by a permanent magnet: a case report and literature review
  125. Regular Articles
  126. HIV/STI prevention interventions: A systematic review and meta-analysis
  127. Regular Articles
  128. Aortic aneurysm as a complication of myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis
  129. Regular Articles
  130. Real-time monitoring of contrast-enhanced ultrasound for radio frequency ablation
  131. Regular Articles
  132. Successful drug-eluting stent implantation in a male patient with dextrocardia: a case report
  133. Regular Articles
  134. Primary pleomorphic liposarcoma of fallopian tube with recurrence: a case report and review of the literature
  135. Regular Articles
  136. Color Doppler Ultrasound in Uterine Arterial Embolization
  137. Regular Articles
  138. Pattern of alcohol consumption by young people from North Eastern Portugal
  139. Regular Articles
  140. Effects of out-of-hospital continuing nursing on schizophrenia patients' rehabilitation and quality of life
Heruntergeladen am 25.1.2026 von https://www.degruyterbrill.com/document/doi/10.1515/med-2017-0020/html
Button zum nach oben scrollen